Back to Search
Start Over
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment
- Source :
- Seminars in cancer biology, Passiglia, F, Caglevic, C, Giovannetti, E, Pinto, J A, Manca, P, Taverna, S, Listì, A, Gil-Bazo, I, Raez, L E, Russo, A & Rolfo, C 2018, ' Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment ', Seminars in Cancer Biology, vol. 52, no. Pt 2, pp. 259-268 . https://doi.org/10.1016/j.semcancer.2018.01.015
- Publication Year :
- 2018
-
Abstract
- Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors' micro environment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment.
- Subjects :
- 0301 basic medicine
Cancer Research
Settore MED/06 - Oncologia Medica
medicine.medical_treatment
Biomarkers
Brain
CTLA4
Immunotherapy
Metastasis
PD1/PDL1
Genomics
Metastasi
Immunomodulation
03 medical and health sciences
0302 clinical medicine
medicine
Biomarkers, Tumor
Cytotoxic T cell
Animals
Humans
Primary (chemistry)
business.industry
Brain Neoplasms
Immunogenicity
Biomarker
medicine.disease
Cancer treatment
030104 developmental biology
030220 oncology & carcinogenesis
Toxicity
Cancer research
Human medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 1044579X
- Database :
- OpenAIRE
- Journal :
- Seminars in cancer biology
- Accession number :
- edsair.doi.dedup.....40b71b1dfaf531ceed0915a34a319060